Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis.

Dursun N, Dursun E, Yalçin S

International journal of clinical practice1 Oct 2001Cited by 33 (Europe PMC)

PMID11695068DOI10.1111/j.1742-1241.2001.tb11111.xPepBankPUB-11695068

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal osteoporosis, vertebral fractures did not differ significantly between calcitonin with calcium and calcium alone.
In plain wordsVertebral fractures did not differ significantly between calcitonin with calcium and calcium alone.
Peptide
Calcitonin-salmon
Outcome
No significant changeNew vertebral fractures
Study
n: not reported in source
Comparator
Calcium alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU daily · intranasal · one yearAs given in this study (human).
Measurements
New vertebral fractures
37.5%
calcitonin group
New vertebral fractures
40%
calcium group
Source sentences
Summary
New vertebral fractures were seen in 31.58% of the alendronate, 37.5% of the calcitonin, and 40% of the calcium groups, representing no statistical difference.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 151 postmenopausal women with lumbar spine BMD 2 SD or more below the young adult mean were randomly assigned to one of three groups:
Summary · context
50 patients intranasal salmon calcitonin 100 IU and oral calcium 1000 mg (calcitonin group), and 50 patients oral calcium 1000 mg (calcium group) daily for one year.
Report a problemFND-1169506804
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, new vertebral fractures did not differ significantly between salmon calcitonin and alendronate, both with calcium.
In plain wordsIn postmenopausal women with osteoporosis, new spine fractures did not differ significantly between salmon calcitonin and alendronate, both with calcium.
Peptide
Calcitonin-salmon
Outcome
No significant changeNew vertebral fractures versus alendronate
Study
n: not reported in source
Comparator
Alendronate 10 mg daily with calcium 1000 mg daily
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU daily · intranasal · one yearAs given in this study (human).
Measurements
New vertebral fractures
37.5%
calcitonin group
New vertebral fractures
31.58%
alendronate group
Source sentences
Summary
New vertebral fractures were seen in 31.58% of the alendronate, 37.5% of the calcitonin, and 40% of the calcium groups, representing no statistical difference.
2 context sentences(design, population, supporting numbers)
Summary · context
51 patients received oral alendronate 10 mg and calcium 1000 mg (alendronate group)
Summary · context
50 patients intranasal salmon calcitonin 100 IU and oral calcium 1000 mg (calcitonin group), and 50 patients oral calcium 1000 mg (calcium group) daily for one year.
Report a problemFND-1169506806
03HumanNon-randomized trialEfficacy outcome
In postmenopausal women with osteoporosis, BMD at all sites increased significantly with intranasal salmon calcitonin plus calcium, but not with calcium alone.
In plain wordsIn postmenopausal women with osteoporosis, bone density at all sites rose significantly with salmon calcitonin plus calcium, but not with calcium alone.
Peptide
Calcitonin-salmon
Outcome
IncreaseBMD at all assessed sites
Study
n = 50
Comparator
Oral calcium 1000 mg alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU daily · intranasal · one yearAs given in this study (human).
Source sentences
Summary
Significant increases in BMD at all sites were obtained in the calcitonin and alendronate groups, but not in the calcium group.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 151 postmenopausal women with lumbar spine BMD 2 SD or more below the young adult mean were randomly assigned to one of three groups:
Summary · context
50 patients intranasal salmon calcitonin 100 IU and oral calcium 1000 mg (calcitonin group), and 50 patients oral calcium 1000 mg (calcium group) daily for one year.
Report a problemFND-1169506801
04HumanNon-randomized trialEfficacy outcome
In postmenopausal women with osteoporosis, pain improved significantly with intranasal salmon calcitonin plus calcium, but not with calcium alone.
In plain wordsIn postmenopausal women with osteoporosis, pain improved significantly with salmon calcitonin plus calcium, but not with calcium alone.
Peptide
Calcitonin-salmon
Outcome
DecreasePain
Study
n = 50
Comparator
Oral calcium 1000 mg alone
Outcome group
Pain · Musculoskeletal
Studied dose
100 IU daily · intranasal · one yearAs given in this study (human).
Source sentences
Summary
Pain and quality of life improved significantly in both the calcitonin and alendronate groups, but not in the calcium group.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 151 postmenopausal women with lumbar spine BMD 2 SD or more below the young adult mean were randomly assigned to one of three groups:
Summary · context
50 patients intranasal salmon calcitonin 100 IU and oral calcium 1000 mg (calcitonin group), and 50 patients oral calcium 1000 mg (calcium group) daily for one year.
Report a problemFND-1169506802
05HumanNon-randomized trialEfficacy outcome
In postmenopausal women with osteoporosis, quality of life improved significantly with intranasal salmon calcitonin plus calcium, but not with calcium alone.
In plain wordsIn postmenopausal women with osteoporosis, quality of life improved significantly with salmon calcitonin plus calcium, but not with calcium alone.
Peptide
Calcitonin-salmon
Outcome
Direction not reportedQuality of life
Study
n = 50
Comparator
Oral calcium 1000 mg alone
Outcome group
Quality of life · Whole body
Studied dose
100 IU daily · intranasal · one yearAs given in this study (human).
Source sentences
Summary
Pain and quality of life improved significantly in both the calcitonin and alendronate groups, but not in the calcium group.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 151 postmenopausal women with lumbar spine BMD 2 SD or more below the young adult mean were randomly assigned to one of three groups:
Summary · context
50 patients intranasal salmon calcitonin 100 IU and oral calcium 1000 mg (calcitonin group), and 50 patients oral calcium 1000 mg (calcium group) daily for one year.
Report a problemFND-1169506803
06HumanNon-randomized trialSafety outcome
In postmenopausal women with osteoporosis, no serious side effects occurred during salmon calcitonin treatment.
In plain wordsIn postmenopausal women with osteoporosis, no serious side effects occurred during salmon calcitonin treatment.
Peptide
Calcitonin-salmon
Outcome
Not applicableSerious side effects
Study
n = 50
Outcome group
Adverse events · Whole body
Studied dose
100 IU daily · intranasal · one yearAs given in this study (human).
Source sentences
Summary
No serious side-effects were seen in any of the patients during follow-up.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 151 postmenopausal women with lumbar spine BMD 2 SD or more below the young adult mean were randomly assigned to one of three groups:
Summary · context
50 patients intranasal salmon calcitonin 100 IU and oral calcium 1000 mg (calcitonin group), and 50 patients oral calcium 1000 mg (calcium group) daily for one year.
Report a problemFND-1169506805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.